EGFR-IN-47
Based on 1 Customer Validation
EGFR-IN-47 is a potent and orally active EGFRL858R/T790M/C797S inhibitor with an IC50 of 0.01 μM. EGFR-IN-47 induces cell cycle attest and cell apoptosis. EGFR-IN-47 has the potential for the research of NSCLC.
For research use only. We do not sell to patients.
- Purity : 96.01%
- CAS No.: 3034649-73-2
- Formula: C29H35N7
- Molecular Weight:481.64
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
All EGFR Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
EGFRL858R/T790M/C797S 0.07 μM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-431 | IC50 |
2.972 μM
Compound: 14aj
|
Antiproliferative activity against human A-431 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human A-431 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 35447433] |
| A549 | IC50 |
1.031 μM
Compound: 14aj
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 35447433] |
| PC-9 | IC50 |
0.013 μM
Compound: 14aj
|
Antiproliferative activity against human PC-9 cells expressing EGFR L858R/T790M/C797S mutant assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human PC-9 cells expressing EGFR L858R/T790M/C797S mutant assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 35447433] |
| PC-9 | IC50 |
0.013 μM
Compound: 36
|
Antiproliferative activity against human PC-9 cells harboring EGFR L858R/T790M/C797S triple mutant assessed as cell growth inhibition
Antiproliferative activity against human PC-9 cells harboring EGFR L858R/T790M/C797S triple mutant assessed as cell growth inhibition
|
[PMID: 36417820] |
In Vitro
EGFR-IN-47 (compound 14aj) (72 h) shows anti-proliferative effects with IC50s of 0.013 μM, 2.972 μM, 1.031 μM for PC-9 (EGFRL858R/T790M/C797S), A432, A549 cells, respectively[1].
EGFR-IN-47 (0.01, 0.05, 0.25, 1 μM; 24 h) induces cell cycle attest at the G0/G1-phase[1].
EGFR-IN-47 (0.01, 0.05, 0.25 μM) induces cell deathvia apoptosis in a concentration-dependent manner[1].
EGFR-IN-47 (0.01, 0.05, 0.25, 1 μM) inhibits phosphorylation of the EGFR downstream mediators[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:PC-9 (EGFRL858R/T790M/C797S), A432, A549 cells
-
Concentration:
-
Incubation Time:72 h
-
Result:Showed anti-proliferative effects with IC50s of 0.013 µM, 2.972 µM, 1.031 µM for PC-9 (EGFRL858R/T790M/C797S), A432, A549 cells, respectively.
-
Cell Line:PC-9 EGFRL858R/T790M/C797S cells
-
Concentration:0.01, 0.05, 0.25, 1 µM
-
Incubation Time:24 h
-
Result:Cells were arrest at the G0/G1-phase.
-
Cell Line:PC-9 EGFRL858R/T790M/C797S cells
-
Concentration:0.01, 0.05, 0.25 µM
-
Incubation Time:24 h
-
Result:Induced cell deathvia apoptosis in a concentration-dependent manner.
-
Cell Line:PC-9 EGFRL858R/T790M/C797S cells
-
Concentration:0.01, 0.05, 0.25, 1 µM
-
Incubation Time:
-
Result:Inhibited phosphorylation of the EGFR downstream mediators.
In Vivo
EGFR-IN-47 (20 mg/kg for i.v.; 20 mg/kg for p.o.) shows an ideal oral bioavailability of 66.05%[1].
Pharmacokinetic Parameters of JAK1/TYK2-IN-2 in Male Sprague-Dawley rats[1].
| parameter | iv (20 mg/kg) | po (20 mg/kg) |
| AUC0-∞ (mg/Lh) | 15.889 | 10.494 |
| Cmax (mg/L) | 6.845 | 0.77 |
| Tmax (h) | 0.083 | 6 |
| F (%) | 66.05 | |
| MRT0-∞ (h) | 16.439 | 16.791 |
| Vss (L/kg) | 16.015 | 28.101 |
| CL (L/h/kg) | 1.272 | 2.151 |
| t(1/2) (h) | 8.922 | 11.154 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6-8 weeks, BALB/c nude mice (PC-9 EGFRL858R/T790M/C797S cells )[1]
-
Dosage:10, 20, 40 mg/kg (dissolved in 25% (v/v) PEG400 plus 5% DMSO)
-
Administration:I.g.
-
Result:Showed anti-tumor effect with low toxicity.
-
Animal Model:Male Sprague-Dawley rats[1]
-
Dosage:20 mg/kg
-
Administration:I.v.; p.o.
-
Result:Showed an ideal oral bioavailability of 66.05%.
Chemical Information
-
CAS No. 3034649-73-2
-
Appearance Solid
-
Molecular Weight 481.64
-
Formula C29H35N7
-
Color Light yellow to yellow
-
SMILES
CN(CC1)CCN1C2=CC=C(C=C2)NC3=NC=C4C=C(N(C4=N3)C5CCCC5)CNC6=CC=CC=C6
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 20 mg/mL (41.52 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0762 mL | 10.3812 mL | 20.7624 mL | 51.9060 mL |
| 5 mM | 0.4152 mL | 2.0762 mL | 4.1525 mL | 10.3812 mL | |
| 10 mM | 0.2076 mL | 1.0381 mL | 2.0762 mL | 5.1906 mL | |
| 15 mM | 0.1384 mL | 0.6921 mL | 1.3842 mL | 3.4604 mL | |
| 20 mM | 0.1038 mL | 0.5191 mL | 1.0381 mL | 2.5953 mL | |
| 25 mM | 0.0830 mL | 0.4152 mL | 0.8305 mL | 2.0762 mL | |
| 30 mM | 0.0692 mL | 0.3460 mL | 0.6921 mL | 1.7302 mL | |
| 40 mM | 0.0519 mL | 0.2595 mL | 0.5191 mL | 1.2976 mL |